USPSTF ruling ‘marks the turn’ for Exact Sciences shares, says Evercore ISI

After the U.S. Supreme Court upheld the structure of the U.S. Preventive Services Task Force and the requirement for payers to cover preventative services with no co-pay, Evercore ISI said the event “marks the turn” for Exact Sciences (EXAS) shares. The firm noted that investor concerns had revolved around if USPSTF is deemed unconstitutional, then all recommendations would be illegal and some commercial payers may start mandating co-pays. If patient copays lowered testing volume, then it would impact companies like Exact Sciences and Hologic (HOLX), but the ruling puts an end to this debate. The analyst added that a series of catalysts makes Exact Sciences’ setup “very interesting” into the second half of the year.